

Study of investigational fianlimab with cemiplimab and chemotherapy in patients with advanced non-small cell lung cancer




Primary Objective: evaluate the efficacy of fianlimab with cemiplimab and chemotherapy in patients with previously untreated, unresectable, advanced NSCLC regardless of PD-L1 expression



PATIENTS WITH ADVANCED NSCLC (N≈950)

INTERVENTION



Primary Endpoints

Phase 2: Objective response rate^{a,b}

Phase 3: Overall survival

Secondary Endpoints

Phase 2: Overall survival
Safety and tolerability
Overall response rate
Disease control rate^{b,c}

Time to tumor response^{b,c}
Duration of response^{b,c}
Progression-free survival^{b,c}
Immunogenicity

Phase 2 and 3: Pharmacokinetics
Phase 2 and 3: Quality of Life



FIND OUT MORE

Scan here to find out more about this study at <https://clinicaltrials.gov/ct2/show/NCT05800015>

This information is intended for investigators interested in open clinical trials.

The use of fianlimab + cemiplimab described herein is investigational and has not been evaluated by any regulatory authority. Please see full prescribing information in your country for cemiplimab.

^aAssessed using Response Evaluation Criteria in Solid Tumors (RECIST). ^bBased on Blinded Independent Central Review (BICR).

^cBased on investigator assessment.

IV, intravenous; N, number of patients; NSCLC, non small-cell lung cancer; Q3W, administered every three weeks; R, randomized.

FIANLIMAB

An Investigational LAG-3 Monoclonal Antibody¹

Designed to bind to LAG-3 on T cells to block the LAG-3 inhibitory signal²



CEMIPLIMAB

An Investigational, Fully Human PD-1 Monoclonal Antibody

Designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation³

SELECTED INCLUSION CRITERIA^a



Stage IIIB or IIIC NSCLC patients who are not candidates for surgical resection or chemoradiation or patients with metastatic disease with no prior systemic treatment



A valid result of PD-L1, regardless of expression level using an assay as performed by a central laboratory



Radiographically measurable lesion by CT or MRI per RECIST v1.1



ECPG PS 0 or 1



Adequate organ and bone marrow function



For more information, visit www.clinicaltrials.gov or please call 844 REGN-MID.

NCT05800015

<https://clinicaltrials.gov/ct2/show/NCT05800015>

This information is intended for investigators interested in open clinical trials. The use of fianlimab + cemiplimab described herein is investigational and has not been evaluated by any regulatory authority. Please see full prescribing information in your country for cemiplimab.

^aInclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on clinicaltrials.gov for complete details. ^bPatients are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

^cPatients who have received prior systemic therapies are excluded with the exception of the following:

- Prior platinum-based doublet chemotherapy if recurrent or metastatic disease develops >6 months after completing therapy and toxicities (excluding alopecia and peripheral neuropathy) resolved to CTCAE grade ≤1 or baseline;
- (Neo)adjuvant anti-PD(L)1 +/- LAG-3 if the last dose is >12 months prior to enrollment;
- Exposure to other immunomodulatory or vaccine therapies if the last dose is >3 months prior to enrollment, immune-mediated AEs have resolved to CTCAE grade ≤1 or baseline by the time of enrollment, and endocrine immune-mediated AEs are controlled.

ALK, anaplastic lymphoma kinase; CT, computerized tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; LAG-3, lymphocyte activation gene-3; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed cell death protein/ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors; ROS1, ROS proto-oncogene 1.

Current per clinicaltrials.gov as of September 15, 2023.

1. Hamid O, et al. *J Clin Oncol*. 2021;39(Suppl. 15):abstr 9515. 2. Goldberg MV, Drake CG. *Curr Top Microbiol Immunol*. 2011;344:269–278. 3. Markham A, Duggan S. *Drugs*. 2018;78(17):1841-1846. FIA-EM-0011 October 2023.

©2023 Regeneron Pharmaceuticals, Inc. All rights reserved.

SELECTED EXCLUSION CRITERIA^a



Active or untreated brain metastases, or spinal cord compression^b



Tumors expressing EGFR mutations, ALK rearrangement, or ROS1 fusions



Ongoing or recent evidence (within 2 years) of an autoimmune disease that required systemic treatment with immunosuppressive agents



Treatment with prior systemic therapies^c



Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment.



History of interstitial lung disease



Known primary immunodeficiencies either cellular or combined T- and B-cell immunodeficiencies